MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 146 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $222,000 | -27.0% | 3,100 | 0.0% | 0.06% | -22.8% |
| Q1 2022 | $304,000 | -36.0% | 3,100 | -44.6% | 0.08% | -33.6% |
| Q4 2021 | $475,000 | +6.3% | 5,600 | 0.0% | 0.12% | 0.0% |
| Q3 2021 | $447,000 | -18.0% | 5,600 | 0.0% | 0.12% | +4.4% |
| Q2 2021 | $545,000 | -16.8% | 5,600 | 0.0% | 0.11% | -26.5% |
| Q1 2021 | $655,000 | -10.8% | 5,600 | -15.2% | 0.16% | -28.9% |
| Q4 2020 | $734,000 | -6.4% | 6,600 | 0.0% | 0.22% | -14.5% |
| Q3 2020 | $784,000 | +5.0% | 6,600 | 0.0% | 0.26% | +18.1% |
| Q2 2020 | $747,000 | -17.7% | 6,600 | -51.5% | 0.22% | -43.0% |
| Q1 2020 | $908,000 | -26.7% | 13,600 | 0.0% | 0.38% | -10.8% |
| Q4 2019 | $1,239,000 | +117.8% | 13,600 | +106.1% | 0.42% | +98.6% |
| Q3 2019 | $569,000 | -17.8% | 6,600 | 0.0% | 0.21% | -17.7% |
| Q2 2019 | $692,000 | -16.3% | 6,600 | 0.0% | 0.26% | -27.2% |
| Q1 2019 | $827,000 | +11.2% | 6,600 | 0.0% | 0.36% | -3.5% |
| Q4 2018 | $744,000 | – | 6,600 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |